Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK AMPLIFICATION
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Two out of 11 patients with an acquired crizotinib resistance showed new ALK copy-number gain (defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen), both with >4 fold increase. One of them also harbored a resistance mutation (G1269A).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/766
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/170
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 22235099
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Resitance or Non-Reponse | true |